Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Andrew_Hirsch
|
| gptkbp:collaboratesWith |
gptkb:Biogen
gptkb:Roche gptkb:Calico_Life_Sciences |
| gptkbp:focus |
oncology
protein degradation |
| gptkbp:foundedYear |
2015
|
| gptkbp:founder |
gptkb:Stuart_L._Schreiber
gptkb:Andrew_Phillips gptkb:Marc_Cohen gptkb:Keith_Dionne |
| gptkbp:headquartersLocation |
gptkb:Watertown,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
C4 Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:CFT1946
CFT7455 CFT8634 |
| gptkbp:platform |
targeted protein degradation
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:CCCC
|
| gptkbp:therapeuticArea |
gptkb:cancer
solid tumors hematologic malignancies |
| gptkbp:website |
https://www.c4therapeutics.com/
|
| gptkbp:bfsParent |
gptkb:Arsenal_Yards
gptkb:Alexandria_Venture_Investments |
| gptkbp:bfsLayer |
6
|